Encompass Health (NYSE:EHC – Get Rating) had its price objective increased by research analysts at Bank of America from $69.00 to $74.00 in a research note issued on Friday, The Fly reports. Bank of America‘s price target would indicate a potential upside of 16.65% from the stock’s current price.
A number of other research firms have also weighed in on EHC. StockNews.com started coverage on Encompass Health in a research note on Thursday, March 16th. They issued a “hold” rating for the company. Deutsche Bank Aktiengesellschaft increased their price objective on Encompass Health from $62.00 to $70.00 in a research note on Thursday, February 9th. Truist Financial lifted their target price on shares of Encompass Health from $70.00 to $75.00 and gave the stock a “buy” rating in a research note on Thursday, February 9th. Barclays increased their price target on shares of Encompass Health from $57.00 to $61.00 and gave the company an “equal weight” rating in a research report on Tuesday, April 4th. Finally, Credit Suisse Group boosted their price objective on shares of Encompass Health from $62.00 to $73.00 and gave the company an “outperform” rating in a research report on Thursday, February 9th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Encompass Health currently has a consensus rating of “Moderate Buy” and an average price target of $69.82.
Encompass Health Stock Performance
NYSE:EHC opened at $63.44 on Friday. Encompass Health has a 1-year low of $44.33 and a 1-year high of $69.77. The company has a debt-to-equity ratio of 1.50, a current ratio of 1.25 and a quick ratio of 1.25. The business has a 50 day moving average of $57.70 and a 200 day moving average of $57.37. The company has a market capitalization of $6.33 billion, a price-to-earnings ratio of 23.50, a PEG ratio of 1.49 and a beta of 1.05.
Encompass Health (NYSE:EHC – Get Rating) last announced its quarterly earnings data on Tuesday, February 7th. The company reported $0.88 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.03. Encompass Health had a net margin of 5.54% and a return on equity of 16.15%. The company had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. On average, sell-side analysts predict that Encompass Health will post 3.07 earnings per share for the current fiscal year.
Insider Transactions at Encompass Health
In related news, CFO Douglas E. Coltharp sold 17,895 shares of the company’s stock in a transaction on Friday, February 10th. The stock was sold at an average price of $60.78, for a total value of $1,087,658.10. Following the sale, the chief financial officer now directly owns 53,097 shares of the company’s stock, valued at $3,227,235.66. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 2.70% of the company’s stock.
Institutional Trading of Encompass Health
A number of institutional investors and hedge funds have recently modified their holdings of EHC. New York State Teachers Retirement System boosted its holdings in shares of Encompass Health by 0.8% during the 1st quarter. New York State Teachers Retirement System now owns 65,834 shares of the company’s stock valued at $3,562,000 after acquiring an additional 538 shares during the last quarter. Benjamin Edwards Inc. grew its position in Encompass Health by 142.6% in the 1st quarter. Benjamin Edwards Inc. now owns 575 shares of the company’s stock worth $31,000 after purchasing an additional 338 shares during the period. Arizona State Retirement System raised its stake in Encompass Health by 2.7% during the 1st quarter. Arizona State Retirement System now owns 28,914 shares of the company’s stock valued at $1,564,000 after buying an additional 759 shares during the last quarter. Strs Ohio lifted its stake in shares of Encompass Health by 15.4% in the 1st quarter. Strs Ohio now owns 169,025 shares of the company’s stock worth $9,144,000 after purchasing an additional 22,619 shares during the period. Finally, Financial Life Advisors bought a new position in Encompass Health in the first quarter worth approximately $556,000. Institutional investors own 96.14% of the company’s stock.
About Encompass Health
Encompass Health Corp. engages in the provision of post-acute healthcare services. It operates through the Inpatient Rehabilitation and Home Health and Hospice segments. The Inpatient Rehabilitation segment operates inpatient rehabilitation hospitals that provide rehabilitative treatment and care to patients who are recovering from stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions and amputations.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Encompass Health, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Encompass Health wasn’t on the list.
While Encompass Health currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: marketbeat.com
